Quantum BioPharma Launches $7 Million Whistleblower Program Targeting Stock Manipulation
Quantum BioPharma has implemented a public whistleblower policy offering up to $7 million for verifiable evidence of stock manipulation, demonstrating the company's commitment to market integrity amid ongoing legal proceedings.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has launched a public whistleblower program offering cash rewards of up to $7 million for verifiable evidence of stock manipulation involving the company's shares. The initiative, approved by the board and audit committee with input from multiple law firms, represents one of the largest corporate whistleblower rewards in recent biopharmaceutical industry history.
The program encourages individuals to submit information directly to reward@quantumbiopharma.com or by calling 1-833-571-1811. Payments will be made from the net proceeds of the company's ongoing lawsuit, with rewards granted only if the submitted information materially contributes to a final, non-appealable judgment or binding settlement in Quantum BioPharma's favor. This financial structure ensures the program is self-funding through the litigation process itself.
Quantum BioPharma's whistleblower policy underscores the company's commitment to transparency, accountability, and market integrity while encouraging simultaneous reporting to both U.S. and Canadian regulatory authorities. The company develops innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders, making market stability crucial for its ongoing research and development efforts. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also maintains strategic investments through FSD Strategic Investments Inc. and retains significant ownership in Unbuzzd Wellness Inc., formerly Celly Nutrition Corp. Additional information about the company is available at https://ibn.fm/QNTM. The full press release detailing the whistleblower program can be viewed at https://ibn.fm/d6YUb.
This substantial reward program comes at a time when regulatory scrutiny of market manipulation in the biopharmaceutical sector has intensified globally. By offering one of the largest corporate whistleblower incentives on record, Quantum BioPharma signals its determination to protect shareholder value and maintain fair market conditions for its publicly traded securities across both NASDAQ and the Canadian Securities Exchange.